Recombinant Human PD-L1 Protein

重组人PD-L1蛋白 | 重组人PD-L1蛋白

B7 H | B7 H1 | B7 homolog 1 | B7-H1 | B7H | B7H1 | CD 274 | CD-274 | CD274 | CD274 antigen | CD274 molecule | MGC142294 | MGC142296 | OTTHUMP00000021029 | PD L1 | PD-L1 | PD1L1_HUMAN | PDCD1 ligand 1 | PDCD1L1 | PDCD1LG1 | PDL 1 | PDL1 | Programmed cell d

rp169666-50μg

50μg

无动物源

≥95%(SDS-PAGE)

Purity: ≥95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

Immobilized Recombinant Human PD-L1 Protein (rp169666) at 2.0 μg/mL can bind Sugemalimab (anti-PD-L1) (Ab175662) with the EC50 of 169.70 ng/mL. Immobilized Recombinant Human PD-L1 Protein (rp169666) at 1.0 μg/mL can bind Avelumab (anti-PD-L1) (A412006) with the EC50 of 77.96 ng/mL. Immobilized Recombinant Human PD-L1 Protein (rp169666) at 1.0 μg/mL can bind Envafolimab (anti-PD-L1) (Ab170617) with the EC50 of 339.40 ng/mL. Immobilized Recombinant Human PD-L1 Protein (rp169666) at 1.0 μg/mL can bind Durvalumab (anti-PD-L1) (D412005) with the EC50 of 35.40 ng/mL.

重组表达

26.1 kDa

C-His

30.7-37.3 kDa, under reducing conditions; 28.6-36.2 kDa, under non-reducing conditions.

HEK293 Accession #: Q9NZQ7 | HEK293

<1.0 EU/μg

人(Human)

1-239 aa

MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHHHHHH

Yes

Yes